Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
You may also be interested in...
Merck KGaA Boosts U.S. Generic Market Presence With Genpharm Expansion
Genpharm opens office in New York headed by former Able CEO Robert Mauro.
Merck KGaA Boosts U.S. Generic Market Presence With Genpharm Expansion
Genpharm opens office in New York headed by former Able CEO Robert Mauro.
Able Labs To Withdraw Seven Approved ANDAs, Recall All Products
The company is concerned about the reliability of data underlying the applications and says further ANDA withdrawals could be forthcoming. Able also is suspending manufacturing and distribution operations and recalling all of its products.